What is 226950.KQ's current stock price?

226950.KQ (OliX Pharmaceuticals,Inc) is currently trading at ₩121,200.00 with a market cap of ₩2.55T.

What sector is OliX Pharmaceuticals,Inc in?

OliX Pharmaceuticals,Inc (226950.KQ) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

Back to Market返回行情

226950.KQ OliX Pharmaceuticals,Inc

KOEHealthcare

₩121,200-1.86%LatestMarket Cap: ₩2.55T

As of 2026-08-09 00:19

Why 226950.KQ matters now

OliX Pharmaceuticals,Inc (226950.KQ) is a Korea stock in Healthcare. The latest InvestLog snapshot shows ₩121,200.00 with -1.86% on the session and ₩2.55T in market capitalization.

Valuation context is available even where detailed statement rows are sparse: InvestLog currently shows P/E -201.20, gross margin 93.3%, and operating margin -188.4%.

Valuation

P/E (TTM)

-201.20

PEG

—

P/B

18.61

P/S

142.53

EV/EBITDA

-130.43

DCF Value

—

FCF Yield

-0.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

93.3%

Operating Margin

-188.4%

Net Margin

-70.9%

ROE

-10.7%

ROA

-6.6%

ROIC

-19.1%

Listing Info

Market

Korea

Exchange

KOE

Currency

KRW

Sector

Healthcare

Industry

Biotechnology

Country

OliX Pharmaceuticals, Inc. is a biotechnology firm in the clinical development phase, specializing in the creation of RNA interference (RNAi) treatments. Its primary focus lies in developing therapies for various conditions affecting the skin (dermal), eyes (ophthalmic), and lungs (pulmonary). The company maintains a robust pipeline of experimental medicines, including: For dermatological applications: OLX101 (targeting skin scars), OLX102 (for skin whitening), OLX103 (an atopic dermatitis candidate), OLX104 (addressing hair loss), OLX105 (an anti-wrinkle product), and OLX106 (for diabetic foot ulcers). For ophthalmic disorders: OLX301 (for age-related macular degeneration retinal fibrosis) and OLX304 (for retinitis pigmentosa). For respiratory diseases: OLX201 (lung fibrosis), OLX202 (asthma), and OLX203 (influenza). Other significant programs encompass: OLX401 (neuropathic pain), OLX701 (liver fibrosis), and a distinct OLX701 designated for cancer immunotherapy. Furthermore, OliX Pharmaceuticals has forged strategic partnerships, including a collaborative agreement with Théa to advance SiRNA therapeutics for eye-related diseases, and a research alliance with PCI Biotech Holding ASA. Established in 2010, the company's operations are based in Suwon, South Korea.